Nirmal Bang: Evaluating gCopaxone Opportunity For Potential New Entrants
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Prior to the approval of first generic copy (Sandoz – Glatopa) in 2015, the Copaxone brand had annual sales of $3.5 billion in the U.S.
However, we have seen the opportunity erode faster than expectations as we have witnessed an overall decline in the Copaxone prescription volumes in multiple sclerosis markets where it is positioned.
Between 2015 and now, the product has lost about 700 basis points in market share and seen approximately 20-25% decline in volumes.
Emergence of new treatment options is the primary contributor to the decline in Copaxone’s market share.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.